NCT03742921View on ClinicalTrials.gov

ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

CompletedOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

February 4, 2019

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2023

Conditions
Lymphoma, T-Cell, Peripheral
Interventions
DRUG

Istodax

Istodax

Trial Locations (1)

550-0006

Nihon Seimei Hospital, Osaka

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT03742921 - ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma | Biotech Hunter | Biotech Hunter